Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Approval Climate: What Do The Oral Testosterone Reviews Tell Us?

Executive Summary

Second go-round for oral testosterone could have marked new boundary on how far FDA is willing to go in approving new entrants to a market with widespread historic off-label use and CV risks.

You may also be interested in...



Surprise Approval For Clarus' Oral Testosterone Includes Black Box, No REMS

Jatenzo clears US FDA 15 months after second negative advisory committee review. 

Oral Testosterones Might Use REMS, CV Post-Market Study To Win Approval

US FDA advisory committee worries about off-label use of Lipocine's Tlando and Clarus' Jatenzo.

Jatenzo v. Tlando: Similar Issues Did Not Lead To Similar Votes

Two oral testosterone therapies solicited similar concerns, but sometimes different votes from advisory committee members on recommending approval.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel